Latest Earnings Results: Q2 '26
Estimated EPS
-$0.81
Reported EPS
-$0.73
Surprise
+9.56%
Estimated Rev
$67.66M
Reported Rev
$71.25M
Surprise
+5.32%
• Reported GAAP EPS of -$0.73 up 2.67% YoY • Reported revenue of $71.25M up 46.91% YoY • For the year ending December 31, 2026, Rhythm Pharmaceuticals anticipates approximately $363 million to $397 million in Non-GAAP Operating Expenses, which excludes stock-based compensation and fixed consideration related to in-licensing.
Bullish Takeaway
Rhythm Pharmaceuticals demonstrated strong commercial execution with global revenue growth of 19% sequentially, led by a 38% U.S. revenue increase and robust adoption of IMCIVREE for acquired hypothalamic obesity.
Bearish Takeaway
Rhythm Pharmaceuticals faced a sequential revenue decline in international markets and a $3.8 million retrospective charge in France, contributing to a wider net loss compared to the prior year period.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.73 | -- | -- | N/A |
Q2 '26 | -$0.81 | -$0.73 | 9.56% | BEAT |
Q1 '26 | -$0.82 | -$0.83 | -0.61% | MISSED |
Q4 '25 | -$0.80 | -$0.73 | 9.26% | BEAT |
Q3 '25 | -$0.71 | -$0.82 | -15.80% | MISSED |